Cargando…

Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study

Background Type 2 diabetes mellitus (T2DM) arises due to a range of pathological abnormalities, necessitating a combination therapy to achieve optimal glycemic control. Vildagliptin, an effective and selective DPP-4 inhibitor, and pioglitazone, an insulin sensitizer, offer distinct mechanisms of act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erande, Suhas, Mukhopadhyay, Jotideb, Dange, Amol, Deogaonkar, Anushka, Birla, Ashish, Doshi, Chetan, Revankar, Santosh, B, Sridhar S, Kumar, Neeraj, Kadam, Pramod V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547078/ https://www.ncbi.nlm.nih.gov/pubmed/37795066 http://dx.doi.org/10.7759/cureus.44548

Ejemplares similares

Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
por: Sridhar, GR, et al.
Publicado: (2023)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol
por: Yeu, Rui Qian, et al.
Publicado: (2020)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats
por: Eom, Young Sil, et al.
Publicado: (2016)

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
por: Brandon, Rebecca, et al.
Publicado: (2023)

REAL-world evidence of risk factors and comorbidities in YOUNG Indian adults with type 2 diabetes mellitus: A REAL YOUNG (diabetes) study
por: Saboo, Banshi, et al.
Publicado: (2021)

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Liquid Chromatographic Methods for the Determination of Vildagliptin in the Presence of its Synthetic Intermediate and the Simultaneous Determination of Pioglitazone Hydrochloride and Metformin Hydrochloride
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
por: Liao, Hung-Wei, et al.
Publicado: (2017)

Effects of Linagliptin and Pioglitazone on Fracture Healing in an Experimental Type 2 Diabetes Rat Model
por: Mraja, Hamisi M, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control
por: Phadke, Dr Uday, et al.
Publicado: (2023)

Healthcare Practitioners' Perspective of Prevailing Awareness on Diabetes Complications: A Questionnaire-Based Pan-India Study
por: Tandon, Nikhil, et al.
Publicado: (2023)

Simultaneous Estimation of Metformin and Pioglitazone by Ultraviolet Spectrophotometry
por: Goswami, Laxmi, et al.
Publicado: (2010)

Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review
por: Sheikh, Ibrahimkhalil M, et al.
Publicado: (2023)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

SAT-141 Effect of Vildagliptin versus Glibenclamide on Glycemic Variability and Endothelial Function in Individuals with Type 2 Diabetes and Hypertension: A Randomized Controlled Trial
por: Cosenso-Martin, Luciana, et al.
Publicado: (2019)

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

MON-673 Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-Alcoholic Steatohepatitis
por: DeBoer, Mark Daniel, et al.
Publicado: (2020)

Effects of Exercise, Metformin, Pioglitazone and Exenatide Treatment on Inflammation Induced Insulin Resistance and Ubiquitin Proteasome System in Diabetes and Obesity
por: Akarsu, Ersin, et al.
Publicado: (2021)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
por: Kim, Nam Hoon, et al.
Publicado: (2017)

Metformin Sustained-Release and Vildagliptin Fixed-Dose Combination for Optimizing Glycemic Control: A Review with Real-World Case Reports
por: Chawla, Manoj, et al.
Publicado: (2023)

The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population
por: Bhattacharjee, Rana, et al.
Publicado: (2023)

SUN-LB032 Severe Insulin Resistance and Nephrotic Range Proteinuria Reversed by Pioglitazone in a Patient With Dunnigan Type Lipodystrophy
por: Sharma, Anjul, et al.
Publicado: (2019)

Role of clinical parameters and early noncontrast magnetic resonance imaging scan of brain in prediction of final neurologic outcome of hanging victims
por: Mazumdar, Srijan, et al.
Publicado: (2010)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sm5q034mbc8unlgfhf1tuiuf7o